Novavax (NASDAQ:NVAX) Stock Rating Raised to “Buy” at Wall Street Zen

Wall Street Zen upgraded shares of Novavax (NASDAQ:NVAX) from a hold rating to a buy rating in a report issued on Saturday morning,Wall Street Zen reports.

Other equities research analysts also recently issued research reports about the company. B. Riley Financial reiterated a “buy” rating and set a $16.00 price target (down from $18.00) on shares of Novavax in a report on Friday. Citigroup reissued a “sell” rating and issued a $8.00 price target (up from $7.00) on shares of Novavax in a research report on Thursday, October 15th. Weiss Ratings restated a “sell (d)” rating on shares of Novavax in a research note on Monday, November 2nd. Zacks Research downgraded shares of Novavax from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 6th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Novavax in a research note on Tuesday, October 27th. Five analysts have rated the stock with a Buy rating, two have given a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $12.33.

Novavax Stock Performance

Shares of NVAX opened at $10.78 on Friday. The stock has a 50 day moving average price of $10.56 and a two-hundred day moving average price of $9.35. The firm has a market capitalization of $1.78 billion, a P/E ratio of -23.43 and a beta of 2.65. Novavax has a 52 week low of $6.20 and a 52 week high of $13.39.

Novavax (NASDAQ:NVAX) last posted its earnings results on Thursday, November 5th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.16. Novavax had a negative return on equity of 14.82% and a negative net margin of 18.64%. The company had revenue of $68.30 million for the quarter, compared to analyst estimates of $50.42 million. During the same quarter last year, the company earned ($1.25) earnings per share. The company’s revenue for the quarter was down 3.0% on a year-over-year basis. On average, equities analysts forecast that Novavax will post -0.38 earnings per share for the current year.

Hedge Funds Weigh In On Novavax

Hedge funds and other institutional investors have recently modified their holdings of the business. Allspring Global Investments Holdings LLC raised its holdings in shares of Novavax by 4.5% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 27,820 shares of the biopharmaceutical company’s stock valued at $295,000 after buying an additional 1,207 shares in the last quarter. KBC Group NV lifted its position in Novavax by 34.9% in the 1st quarter. KBC Group NV now owns 4,746 shares of the biopharmaceutical company’s stock worth $39,000 after buying an additional 1,229 shares during the last quarter. Allworth Financial LP boosted its stake in Novavax by 292.5% in the second quarter. Allworth Financial LP now owns 4,353 shares of the biopharmaceutical company’s stock worth $41,000 after buying an additional 3,244 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in Novavax by 15.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 30,096 shares of the biopharmaceutical company’s stock worth $326,000 after buying an additional 3,926 shares in the last quarter. Finally, Abel Hall LLC boosted its stake in Novavax by 30.7% in the first quarter. Abel Hall LLC now owns 18,050 shares of the biopharmaceutical company’s stock worth $147,000 after buying an additional 4,241 shares in the last quarter. Hedge funds and other institutional investors own 53.04% of the company’s stock.

Novavax News Roundup

Here are the key news stories impacting Novavax this week:

• Positive Sentiment: Novavax reported a Q3 loss of $0.19 per share, narrower than analysts’ expected $0.35 loss, while revenue of $68.3 million topped estimates of about $50.4 million. The loss also improved from $0.62 per share a year earlier. Article: Novavax Reports Q3 Loss, Tops Revenue Estimates
• Positive Sentiment: The company raised its 2026 revenue outlook to $385 million–$415 million, or $400 million at the midpoint—about $145 million higher than its prior framework. A $125 million milestone from Sanofi, earned after a Phase 3 trial launch, accounts for much of the increase. Novavax also reduced operating expenses and said its cash runway extends into 2029. Article: Novavax boosts 2026 revenue forecast as licensing deals pay off
• Neutral Sentiment: B. Riley reaffirmed its Buy rating, though it lowered its price target to $16 from $18. The reduced target tempers the otherwise positive analyst stance. Article: B. Riley stock recommendations
• Negative Sentiment: Investors may be focused on Novavax pushing its profitability target out to 2029. Q3 revenue was still down 3% year over year, and the higher 2026 outlook depends substantially on the Sanofi milestone, raising questions about the durability of revenue growth. Article: Novavax pushes profitability target to 2029, shares dip

Novavax Company Profile

Novavax, Inc is a biotechnology company focused on developing and commercializing vaccines for infectious diseases. The company uses recombinant protein nanoparticle technology and its proprietary Matrix-M adjuvant to develop vaccines designed to stimulate targeted immune responses.

Novavax’s principal commercial product is Nuvaxovid, also known as the Novavax COVID-19 vaccine, a protein-based vaccine developed to help prevent COVID-19. The vaccine has been authorized or approved in various markets, subject to local regulatory requirements, and the company has worked with governments, public-health organizations, and pharmaceutical partners to support its distribution internationally.

Founded in 1987, Novavax is headquartered in Gaithersburg, Maryland.